Fulgent Genetics COO sells 1,128 shares for RSU tax withholding at $22.03
Rhea-AI Filing Summary
Xie Jian, President and COO of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,128 shares of the issuer's common stock on 09/03/2025 at a weighted-average sale price of $22.0267 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/28/2022. After the reported sale, Mr. Xie beneficially owned 364,121 shares directly and held an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, dated January 27, 2010. The Form 4 was executed by Paul Kim as attorney-in-fact.
Positive
- Transaction disclosed clearly: the sale is explicitly described as tax-withholding related to RSU vesting.
- Detailed price disclosure: weighted-average sale price ($22.0267) and price range ($21.92–$22.175) are provided.
- Continued significant holdings: reporting person retains 364,121 direct shares plus 220,816 indirect shares via trust.
Negative
- Reduction in direct holdings: 1,128 shares were sold, decreasing the reporting person's direct stake.
- Insider sale may be read negatively by some investors despite being for tax withholding purposes.
Insights
TL;DR: Insider sale appears to be a routine tax-withholding disposition tied to RSU vesting, not a directional signal about company performance.
The filing documents a small, clearly labeled sale to cover tax liabilities from vested restricted stock units. The transaction is described as multiple sales aggregated to a weighted-average price and does not indicate additional derivative activity or a change in control. The report also discloses indirect holdings via a family trust with a disclaimer of beneficial interest, which is standard governance disclosure. Overall, this is a routine insider administrative transaction.
TL;DR: The sale of 1,128 shares is immaterial relative to total holdings and stems from RSU tax withholding.
The reported weighted-average sale price was $22.0267, and the explanatory footnote confirms the sale satisfied tax withholding from RSUs originally granted 02/28/2022. Post-transaction direct beneficial ownership remains at 364,121 shares, with 220,816 held indirectly by a family trust. No options or other derivative transactions were reported. This filing provides transparency but does not present new operational or financial information about the issuer.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,128 | $22.0267 | $25K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
